[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@gordon_analysis Andrew Gordon
Andrew Gordon posts on X about $onc, what is, status, $4503t the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX +574%
- X Month XXXXX +110%
- X Months XXXXXX +161%
- X Year XXXXXX +194%
Mentions: X #
- X Week X no change
- X Month XX +33%
- X Months XX +132%
- X Year XXX +28%
Followers: XXX #
- X Week XXX +2.40%
- X Month XXX +3.60%
- X Months XXX +54%
- X Year XXX +168%
CreatorRank: undefined #
Social Influence
Social category influence cryptocurrencies XXXX% finance XXXX%
Social topic influence $onc #3, what is 12.5%, status 12.5%, $4503t 12.5%, what is the 12.5%, tge 12.5%, $lu 12.5%, $path 12.5%, strong 12.5%, $nuvb XXXX%
Top accounts mentioned or mentioned by @annexonbio
Top assets mentioned One Cash (ONC) UiPath, Inc. (PATH)
Top Social Posts
Top posts by engagements in the last XX hours
"@annexonbio What is the status of tge BLA filing for ANX005 with the FDA What is the status of European collaborations for ANX005 and ANX007 Given ANX007's favorable position in Europe has ANNX discussed European collaborations with Apellis and Astellas"
X Link 2025-10-29T16:50Z XXX followers, XXX engagements
"$lu Oct. XX 2025 $X calls Volume: 5774"
X Link 2025-09-23T00:06Z XXX followers, XXX engagements
"$PATH - is a $20+ stock. Excellent earnings report. Strong guidance. Collaborations with major tech companies. Disruptive product. Reasonable market capitalization to sales ratio. Add $PATH to $ONC and $NUVB for 2026"
X Link 2025-12-04T11:12Z XXX followers, XXX engagements
"$ONC (BeONe Medicines) reports earnings 11/6. $XXX ONC Q3 2025 earnings call November X 2025 at X AM EST I think that they will publish decent numbers. ONC' s lead product is Brukinsa (to treat CLL)"
X Link 2025-11-05T20:32Z XXX followers, XXX engagements
"$ONC The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to BeOne Medicines New Drug Application for sonrotoclax a next-generation BCL2 inhibitor targeting relapsed or refractory mantle cell lymphoma (MCL) in adult patients previously treated"
X Link 2025-11-26T12:34Z XXX followers, XXX engagements
"$onc Is this morning's drop in price due to the 12/3 FDA approval of pirtobrutinib for adults with r/r cll or sll who have previously been treated with a covalent BTK inhibitor"
X Link 2025-12-05T16:21Z XXX followers, XXX engagements
"$onc I think that pirtobrutinib as a second line treatment will not do much if any harm to ONC. As a second line treatment patients on Brukinsa would have to develop resistance then go to pirtobrutinib. If they develop resistance then they would be off Brukinsa anyway"
X Link 2025-12-05T22:12Z XXX followers, XXX engagements